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The primary etiology of CKD is a direct consequence of initial dysfunction and injury of the
glomerulus, the main filtration system. Podocytes are terminally differentiated epithelial
cells in the glomerulus, whose major function is the maintenance of this renal filtration bar-
rier. Podocyte injury is implicated in many glomerular diseases including focal segmental
glomerular sclerosis and HIV-associated nephropathy. In many of these diseased condi-
tions, the podocyte can either undergo dedifferentiation and proliferation, apoptosis, or
cell detachment. Regardless of the initial type of injury, the podocyte ultimately loses its
functional capacity to maintain the glomerular filtration barrier. Significant injury resulting
in a loss of the podocytes and failure to maintain the renal filtration barrier contributes to
progressive kidney disease. Consequently, therapies that prevent podocyte injury and pro-
mote their regeneration will have a major clinical impact on glomerular disease. Retinoic
acid (RA), which is a derivative of vitamin A, has many cellular functions including induction
of cell differentiation, regulation of apoptosis, and inhibition of inflammation and prolifer-
ation. RA is required for kidney development and is essential for cellular differentiation in
the setting of podocyte injury. The mechanism by which RA directs its beneficial effects is
multifactorial, ranging from its anti-inflammatory and anti-fibrotic effects to a direct effect
of upregulating podocyte differentiation markers in the podocyte. The focus of this review
is to provide an overview of RA in kidney development and glomerular disease. We also
highlight the key mechanism(s) by which RA restores podocyte differentiation markers and
ameliorates glomerular disease.
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INTRODUCTION
More than three decades have passed since the initial description
of retinoids, synthetic derivatives of vitamin A (retinol), in human
physiology (1). Vitamin A is a critical component of our diet since
it cannot be synthesized by our body. It is essential for various
cell processes, including kidney development, epithelial cell dif-
ferentiation, and inhibiting inflammation and cell proliferation
(1–5). The widespread use of vitamin A has been hindered by
its toxicity, with therapeutic doses frequently resulting in com-
plications of hypervitaminosis syndrome (1). Consequently, the
synthesis of first generation derivatives of retinoids, all-trans-
retinoic acid (atRA), proved to improve efficacy while minimizing
toxicity (1). In the canonical retinoic acid (RA) synthesis pathway,
retinol is taken up by retinol-binding protein (RBP) in circulation
and transferred intracellularly, where it is initially metabolized
to retinal by retinol dehydrogenases (RDHs) and transformed
into retinaldehyde by retinaldehyde dehydrogenases (RALDHs),
with eventual oxidation to RA (6). Subsequently, RA exerts its
effect by binding to cytosolic retinoic acid receptors (RAR), which
heterodimerizes with retinoid X receptors (RXR), leading to acti-
vation of RA response elements (RARE) on target genes (6). In the
past two decades, the diverse and critical actions of RA have been
clearly illustrated in several pathological processes, from cancer
biology to skin treatment to kidney disease (3–5). Our objec-
tive in this mini-review is to demonstrate the essential role of
retinoids in kidney disease and development as well as its ther-
apeutic benefits in experimental models of glomerular disease.
Furthermore, we hope to highlight the deep dichotomy between
the numerous basic science studies and the relative dearth of
clinical studies on the therapeutic benefits of retinoids in kidney
disease.
RETINOIC ACID IN KIDNEY DEVELOPMENT
During fetal life, the final nephron number is determined by the
branching of the ureteric bud to develop the complete renal col-
lecting system. Studies have clearly demonstrated that RA signaling
is critical to this branching nephrogenesis and the final nephron
number during kidney development (7–9). This arborization of
the ureteric bud is specifically regulated by RA signaling from
the stromal mesenchyme (9). Batourina et al. demonstrated that
RA from the stromal mesenchyme regulates the expression of
a tyrosine kinase receptor, Ret, in the ureteric bud during kid-
ney development (9). Ret is a proto-oncogene that encodes for a
tyrosine kinase receptor and is expressed from the initial stages
of the Wolffian duct through the development of ureteric bud.
Upon stimulation from RA, the epithelial cells with Ret expression
initiate the outgrowth and subsequent branching of the ureteric
bud (10). Impaired RA signaling directly limits the ureteric bud
branching, thereby hindering the development of the collecting
system (9). In addition, the authors observed that the deletion of
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Rarα and Rarβ2 (isoforms of receptors for RA) in the stromal mes-
enchyme downregulated the expression of Ret in the ureteric bud
and impaired the ureteric bud outgrowth in mice (8, 9). Further-
more, others have confirmed that the expression of these receptors
(Rarα and Rarβ2) is localized to the cells in the stromal mes-
enchyme, rather than in the cells of the developing nephron (8).
Consequently, compound mutations in Rarα and Rarβ2 cause
the stromal precursor cells to remain along the periphery, with
few cells between the collecting ducts in the developing medullary
zone (8). These mutations also contribute to the downregulation
of Ret in the ureteric bud, thereby resulting in limited ureteric bud
branching and small kidney size at birth (8). Thus, this paracrine-
signaling pathway between RA and Ret expression is required
for branching morphogenesis and the development of the renal
collecting system.
Since RA is essential for branching morphogenesis and con-
tributes to the final nephron number, the altered expression
of genes involved in RA metabolism has been associated with
impaired kidney development (11). For instance, mice lacking
in Raldh2, enzyme required for the irreversible oxidation of reti-
naldehyde to RA, are embryonically lethal due to low RA levels and
failed organogenesis (12, 13). Conversely, the authors observed
that homozygosity for a common variant within the promoter
region of the gene encoding for RALDH2, conferred an upregula-
tion in RALDH2 with a subsequent increase in plasma RA levels
and kidney volume in humans. The authors suggest that the pres-
ence of this variant may especially be protective in individuals that
are nutritionally deficient for vitamin A during kidney develop-
ment by maintaining RA signaling (11). Combined, these studies
reveal the essential and protective role of RA signaling in kidney
development.
RETINOIC ACID IN GLOMERULAR DISEASE
Other than the critical role that RA plays in kidney development,
RA has been demonstrated to restore differentiation markers in
cellular injury as well as induce the differentiation of kidney prog-
enitor cells. Furthermore, RA has also been shown to attenuate
inflammation and apoptosis in models of podocyte injury. Finally,
the progression in podocyte injury has been closely linked to RA
metabolism.
RETINOIC ACID SIGNALING IN PODOCYTE DIFFERENTIATION
Podocytes are terminally differentiated visceral epithelial cells in
the glomerulus,whose function is critical to the maintenance of the
glomerular filtration barrier. These highly specialized cells express
distinct podocyte differentiation markers and lack the ability to
proliferate. Previous studies have illustrated that in the setting of
HIV-associated nephropathy (HIVAN) and collapsing focal seg-
mental glomerular sclerosis (FSGS), the podocyte loses its terminal
differentiation markers and reenters the cell cycle, leading to cell
proliferation (14, 15) (Figure 1). RA has clearly been shown to
exhibit anti-proliferative with pro-differentiation effects in multi-
ple tissues, including the kidney and specifically in the podocyte
(16–18).
Earlier studies have demonstrated that treatment with RA
reduced markers of proliferation and preserves podocyte-specific





















FIGURE 1 | Schematic diagram of retinoids in podocyte injury. Retinoic
acid (RA) has been demonstrated to play a critical role in attenuation of
podocyte injury. The mechanism by which RA abrogates podocyte injury is
dependent on the type of inciting injury. Podocyte apoptosis is improved
with RA treatment in a murine model of adriamycin-induced nephropathy,
focal segmental glomerulosclerosis (FSGS) model (green). Podocyte
dedifferentiation is attenuated with RA treatment in models of
HIV-associated nephropathy (HIVAN) (purple). In a murine model of
crescentic glomerulonephritis, using nephrotoxic serum (NTS), RA
treatment minimized parietal epithelial cell (PEC) proliferation (black) and
restored podocytes by PEC trans differentiation (blue).
HIVAN (17). In models of HIVAN, the expression of HIV-1 trans-
gene induces the podocyte to dedifferentiate and reenter the cell
cycle (19). We have demonstrated that treatment with RA abro-
gates this process in a cyclic adenosine monophosphate (cAMP)-
dependent manner (19). For instance, RARα antagonists impede
the production of cAMP and the downstream anti-proliferative
effects in the podocyte. Similarly, the use of cAMP inhibitors
diminished RA-induced podocyte differentiation (19, 20). In con-
trast, the use of cAMP agonists restored the podocyte differenti-
ation effects of RA. Furthermore, the use of phosphodiesterase-4
inhibitor, increased cAMP levels and enhanced the differentiation
effects of RA in cultured human podocytes infected with HIV-1
(19). In addition, the loss of RARα in HIV-1 transgenic (Tg26)
mice resulted in a significant increase in albuminuria and accel-
erated glomerulosclerosis (21). Conversely, RARα agonists, such
as Am580, have shown to attenuate podocyte dedifferentiation in
in vitro and in vivo models of podocyte injury (21). Interestingly,
the concomitant use of phosphodiesterase inhibitor, Roflumilast,
with Am580 resulted in a synergistic therapeutic effect on the
podocyte (22). Combined, these findings suggest that treatment
with RA inhibits podocyte dedifferentiation in a cAMP-dependent
manner (18, 20).
Although RA-mediated podocyte differentiation is cAMP-
dependent, many podocyte differentiation markers lack RARE or
cAMP response element-binding protein (CREB) transcriptional
binding sites. To address the mechanism by which RA-cAMP
signaling mediates podocyte differentiation, recent microarray
studies and comparative promoter analyses were performed (23,
24). These studies revealed that Krüppel-like factor 15 (KLF15)
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transcriptional binding sites exist on many podocyte-specific
genes and may serve as a potential downstream target of CREB (23,
24). In general, KLFs are a subclass of zinc-finger family of DNA-
binding transcriptional regulators that are involved in a broad
range of cellular processes (i.e., cell differentiation, angiogene-
sis, erythropoiesis) (25). Specifically, KLF15 is a kidney-enriched
zinc-finger binding transcription factor that has been shown to
mediate differentiation in various cell types (26). Subsequently, it
was demonstrated that KLF15 is downstream of RA and CREB
and is a critical mediator of RA-induced podocyte differentiation
(24). Furthermore, we observed that the glomerular expression of
KLF15 is reduced in kidney biopsies from patients with HIVAN
and FSGS as compared to healthy control subjects (24). Com-
bined, these recent studies suggest that KLF15 is required for
RA-cAMP-mediated podocyte differentiation.
RETINOIC ACID CONTRIBUTES TO THE GENERATION OF GLOMERULAR
TRANSITION CELLS
In FSGS, podocyte injury is observed with proliferation of epithe-
lial cells in Bowman’s space, a finding which has been defined as a
pseudo-crescent (27). For years, it remained unclear if these were
truly proliferating parietal epithelial cells or merely podocytes that
have lost their differentiation markers and have reentered the cell
cycle (28, 29). Regardless of the origin, RA has been demonstrated
to be critical to this proliferative process (30). For instance, the
mechanism by which RA may regulate the transition of parietal
epithelial cells to podocytes has been closely examined in several
models of podocyte injury (28–31). For instance, in a rat model of
membranous nephropathy (where there is a loss of podocyte dif-
ferentiation markers), RA was shown to restore podocyte number
by increasing the number of epithelial cells expressing podocyte
differentiation markers in the glomerulus (30). Specifically, the
increase in these epithelial transition cells in the glomerulus colo-
calized to Paired box gene 2 (PAX2), parietal epithelial cell marker,
and Wilms-Tumor 1 (WT1), podocyte-specific marker, thereby
suggesting that RA treatment induced the transition of parietal
epithelial cells to podocytes (30). Similarly, the authors confirmed
this using an experimental model of FSGS to illustrate that the
beneficial effect of RA in podocyte regeneration may go beyond
a specific glomerular disease (30). Since podocytes are terminally
differentiated cells with minimal capacity to self-replicate, restora-
tion of these podocytes in the setting of cellular injury is criti-
cal to the recovery of glomerular function. This recent evidence
demonstrates that RA may be essential to this regenerative process.
IMPAIRED RETINOID SIGNALING CONTRIBUTES TO PODOCYTE INJURY
In nephrotic range albuminuria, the sequestration of RA by
albumin prevents podocyte regeneration in murine models of
podocyte injury (31). For instance, it was shown that increas-
ing albuminuria prevents the differentiation of progenitor cells
toward a podocyte lineage (31). Specifically, Peired et al. demon-
strated that sequestration of RA by increasing albuminuria pre-
vented RARE-mediated regulation of podocyte differentiation
markers, which was rescued with administration of RA (31)
(Figure 1). In addition, in vitro studies revealed that albumin
overload impairs podocyte differentiation markers without affect-
ing podocyte survival. The authors also showed that RA-induced
podocyte differentiation was attenuated in the setting of increasing
albumin concentration. Their findings suggest that this process
is mediated via the sequestration of RA by albumin, leading to
downregulation of RARE and worsening podocyte injury (31).
Retinaldehyde dehydrogenase 2 is not only critical to the pro-
duction of RA and kidney development, but RALDH2 levels
are significantly upregulated as a consequence of injury to the
podocyte (32). Using a rat model of podocytopathy (puromycin
treatment), the authors demonstrated that Raldh2 levels increased
with podocyte injury (32). Subsequent RA treatment restored
podocyte differentiation markers in the setting of elevated Raldh2
levels. Conversely, vitamin A deficiency delayed podocyte recovery
in this experimental model (32). This study revealed that both the
substrates and the enzymes involved in RA signaling are required
for podocyte repair after injury (32). Although RALDH2 is critical
to RA production, the rate-limiting step of RA synthesis and its
eventual downstream effects remains the conversion of retinol to
retinal by retinol dehydrogenases (RDHs). Although many RDHs
are critical for RA metabolism, RDH9 was recently demonstrated
to rescue podocytes from injury using two murine models of FSGS,
HIV-1 transgenic model and adriamycin-induced nephropathy
model (33). We demonstrated that the overexpression of RDH9 in
cultured podocytes induced the expression of podocyte-specific
differentiation markers. In addition, podocyte-specific overex-
pression of RDH9, in both models of podocyte injury, attenuated
glomerular injury and podocyte dedifferentiation in mice (33).
Combined, these findings suggest that other than simply using RA
for treatment, critical molecules in the RA synthesis pathway may
serve as a potential therapeutic in the treatment of glomerular
disease.
ANTI-INFLAMMATORY EFFECTS OF RETINOIC ACID
The anti-inflammatory of RA has been demonstrated in multiple
animal models of glomerular disease (19, 34). This is not sur-
prising, considering the observed anti-inflammatory effects of RA
are well-established in other tissues (1). For instance, in vitro and
in vivo models of diabetic kidney disease revealed that treatment
with RA ameliorates podocyte injury. Specifically, the treatment of
cultured podocytes with RA reduced the activation of inflamma-
tory pathways with inhibition of monocyte chemotactic protein-1
(MCP-1) synthesis, which is typically increased in diabetic condi-
tions (34). In addition, the authors showed a reduction in protein-
uria and inhibition of inflammation in RA-treated diabetic rats
(34). Prior studies have also revealed that RA suppresses the tran-
scripts of several pro-inflammatory cytokines and chemokines as
well as the recruitment of macrophages (19). In addition, the anti-
inflammatory role of RA was more evident with its inhibitory
effect in an in vitro model of lipopolysaccharide (LPS)-induced
macrophage production of IL-12 (35). Using this LPS model, the
authors determined that the reduction in IL-12 production by
RA was dependent on inhibition of NFκB activity, a potential
mechanism by which RA reduced inflammation (35).
Retinoic acid has also been demonstrated to exhibit anti-
inflammatory effects in the treatment of primary podocytopathies,
such as MCD. Treatment with RA prevented foot process efface-
ment and reversed albuminuria in puromycin aminoglycoside
nephropathy (PAN) model, a rat model of minimal change disease
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(32, 36). In this study, the authors reveal that RA-treated PAN rats
exhibited less interstitial mononuclear cell infiltration and reduced
expression of fibronectin and MCP-1, which are critical factors for
monocyte infiltration (36). RA has been demonstrated to abro-
gate kidney disease in these murine models of lupus nephritis. For
instance, treatment with RA ameliorated kidney injury and pro-
longed survival in the NZB/W F1 mice, a model of lupus nephritis
(37). Also, RA-treated mice exhibited a reduction in glomerular
IgG deposits as well a reduction in cytokine expression in the
lupus nephritis model (37). These similar effects were observed in
another murine model of lupus nephritis, MRL/lpr mice. Specif-
ically, RA treatment reduced albuminuria, improved glomeru-
lar lesions, and attenuated chemokine and cytokine expression
in the kidney (38). In this model, the authors identified that
the renal transforming-growth factor beta (TGFβ) was concur-
rently elevated with RA treatment, suggesting that TGFβ may
potentially mediate the anti-inflammatory effects of RA (38).
However, future studies are required to precisely define the mech-
anism by which TGFβ mediates RA-induced anti-inflammatory
effects in the glomerulus. In addition, RA has therapeutic bene-
fits in other models of glomerular disease independent of primary
podocytopathies. For instance, treatment with RA reduced cres-
cent formation and improved kidney function in animal models of
anti-GBM disease, with a reduction in markers of inflammation
and proliferation, such as PCNA, TNF-alpha, IL-1B, PDGF, and
C/EBP sigma (16). Regardless of the specific experimental model
of glomerular injury, these studies clearly demonstrate that the
therapeutic benefits of RA in glomerular disease are at least, in
part, mediated by its anti-inflammatory effects.
OTHER POTENTIAL THERAPEUTIC BENEFITS OF RETINOIC ACID IN
GLOMERULAR DISEASE
In addition to the anti-inflammatory effects of RA, treatment with
RA has been demonstrated to reduce apoptosis in murine and cell
culture models of podocyte injury (Figure 1). For instance, admin-
istration of RA to PAN-treated cultured podocytes resulted in inhi-
bition of apoptosis (36). Furthermore, macrophage-specific loss of
RXRα in mice demonstrated reduced clearance of apoptotic cells,
resulting in glomerular injury resembling lupus nephritis (39).
Retinoic acid can also play a synergistic therapeutic role
with other agents in the treatment of kidney disease. Nephrin,
podocyte-specific differentiation marker, expression is induced
by RA and activated vitamin D, 1,25-dihydroxyvitamin D3 (40).
Interestingly, the synergistic increase in nephrin expression is
mediated by selective cooperation between RAR and vitamin D
receptor (VDR) in cell culture models (40). Therefore, future stud-
ies exploring the concomitant use of both these agents in treating
glomerular disease may prove to be efficacious.
Other than the potential use of RA in the treatment of primary
podocytopathies, RA may provide some therapeutic benefit in the
treatment of other glomerular diseases. In a rat model of mesangial
injury,anti-Thy1.1 nephritis, treatment with RA reduced albumin-
uria and improved glomerular lesions (19, 41). Specifically, admin-
istration of RA reduced endothelin-1 and endothelin Type A and
B receptor expression levels, which are critical to the progression
of renal injury (19). This suggests that a potential alternate mech-
anism by which RA treatment may abrogate glomerular injury.
OBSTACLES IN THE CLINICAL USE OF RETINOIC ACID FOR TREATING
GLOMERULAR DISEASE
Retinoids have clearly been demonstrated to have a therapeutic
benefit in experimental models of glomerular disease; however,
its translation from the bench to the bedside has been hindered
by its toxicity. For instance, the strong experimental evidence for
the use of RA in kidney disease had prompted the initiation of
NIH sponsored open-label randomized clinical trial with the use
of Isotretinoin in the treatment of patients with FSGS and col-
lapsing glomerulopathy (NCT00098020) in 2004. However, the
recruitment of subjects has proved to be difficult due to the risk
of toxicity associated with retinoids.
Toxicity of retinoids includes CNS abnormalities, craniofacial
malformation, liver toxicity, hyperlipidemia, reduced spermiogen-
esis, myalgia, arthralgias, and mucocutaneous side effects (1). To
minimize the toxicity and yet retain the therapeutic benefit of RA,
we synthesized and demonstrated that a novel derivative of RARα
agonist, boronic acid retinoid (BD4), attenuated kidney injury in
the HIV-1 transgenic mice. BD4 retains the therapeutic benefit of
RA, but with less toxicity due to metabolic oxidation (42). Specif-
ically, we observed that BD4 binds to RARα and exerts its down-
stream effects with higher affinity and less toxicity as compared to
atRA or Am580 (42). Future research is required to identify agents
such as these with similar efficacy, but with lower toxicity than
atRA. After establishing a safe therapeutic profile, we need to take
the next step in implementing these agents in clinical trials.
CONCLUSION
In conclusion, we provide a brief overview on the essential role of
retinoids in kidney disease. Studies extending for more than three
decades have illustrated the therapeutic benefit of RA in models of
kidney disease. Despite this large body of evidence, clinical studies
demonstrating its therapeutic benefit are lacking. Consequently,
there is a dire need for the synthesis of newer generation retinoids
as well as novel agents involved in RA metabolism that maintain
the therapeutic efficacy of retinoids while minimizing its toxicity.
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